Orexigen Therapeutics (OREX) Shares are Down -10.47%

Orexigen Therapeutics (OREX) has risen sharply, recording gains of 14.93% in the past 4 weeks. However, the stock has corrected -10.47% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 15.17% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 2.78% and the fifty day Moving Average is 5.04%. Orexigen Therapeutics, Inc. has dropped 8.33% during the last three month period . Year-to-Date the stock performance stands at -77.62%.


Orexigen Therapeutics (NASDAQ:OREX): stock turned positive on Friday. Though the stock opened at $3.8, the bulls momentum made the stock top out at $3.86 level for the day. The stock recorded a low of $3.7 and closed the trading day at $3.85, in the green by 0.79%. The total traded volume for the day was 75,781. The stock had closed at $3.82 in the previous days trading.

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.